<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC6380461/results/search/funders/results.xml">
  <result pre="the next installment of this article series. Keywords antibody therapeutics" exact="Food and Drug Administration" post="European Medicines Agency cancer immune-mediated disorders success rates fig-count:"/>
  <result pre="Database, BioMedTracker). Antibody therapeutics developed solely by non-commercial organizations, e.g.," exact="National Institutes of Health," post="and all biosimilar antibodies were excluded. Molecules with at"/>
  <result pre="30, 2018. *Biosimilar products were excluded. #INN assigned by the" exact="World Health Organization;" post="US product names in alphabetical order are burosomab-twza, cemiplimab-rwlc,"/>
  <result pre="United States. Erenumab (Novartis) On May 17, 2018, the US" exact="Food and Drug Administration" post="(FDA) approved erenumab-aooe (Aimovig) for the preventive treatment of"/>
  <result pre="for placebo (p &amp;lt; 0.001). 24 In November 2018, the" exact="European Commission" post="(EC) granted marketing authorization for Emgality® for the prophylaxis"/>
  <result pre="have at least four migraine days per month. Burosumab (KRN23;" exact="Kyowa Hakko Kirin" post="Co. Ltd, Ultragenyx Pharmaceutical Inc.) On February 19, 2018,"/>
  <result pre="February 6, 2019. 29 Caplacizumab was developed by Ablynx, a" exact="Sanofi" post="company. The approval of caplacizumab in the EU was"/>
  <result pre="study were presented at the 59th Annual Meeting of the" exact="American Society of Hematology" post="in December 2017. 30 The HERCULES study recruited 145"/>
  <result pre="Mogamulizumab’s first approval, in 2012, was granted by the Japanese" exact="Ministry of Health," post="Labour and Welfare for treatment of patients with relapsed"/>
  <result pre="complement inhibitor treatment-naïve patients with PNH. 44 Also developed by" exact="Alexion Pharmaceuticals," post="Soliris® was first approved for PNH in 2007. Risankizumab"/>
  <result pre="in the FDA’s complete response letter, as announced by collaborators" exact="Amgen" post="and UCB in July 2017. 47 In July 2018,"/>
  <result pre="Amgen and UCB in July 2017. 47 In July 2018," exact="Amgen" post="and UCB announced that the BLA had been resubmitted,"/>
  <result pre="squamous cell carcinoma. Sintilimab (IBI308; Innovent Biologics) Innovent Biologics and" exact="Eli Lilly and Company" post="are jointly developing sintilimab, a human IgG4 antibody targeting"/>
  <result pre="OMS721 Human mAb MASP-2 Phase 3 Atypical hemolytic uremic syndrome" exact="Novartis" post="Ligelizumab Human IgG1 IgE Phase 3 Chronic spontaneous urticaria"/>
  <result pre="Evinacumab Human mAb Angiopoietin-like 3 Phase 3 Homozygous familial hypercholesterolemia" exact="Novartis" post="Crizanlizumab Humanized IgG2 CD62 (aka P-selectin) Phase 3 Sickle"/>
  <result pre="AstraZeneca/MedImmune LLC Tralokinumab Human IgG4 IL-13 Phase 3 Atopic dermatitis" exact="Novartis" post="Ianalumab (VAY736) Human IgG1 BLyS/BAFF/TACI/BCMA receptor Phase 2/3 Autoimmune"/>
  <result pre="α, β, ω receptor 1 Phase 3 Systemic lupus erythematosus" exact="Genentech" post="Etrolizumab Humanized IgG1 a4-b7/aE-b7 integrin receptor Phase 3 Ulcerative"/>
  <result pre="IgG1 a4-b7/aE-b7 integrin receptor Phase 3 Ulcerative colitis; Crohn’s disease" exact="Boehringer Ingelheim" post="BI655130 Human IgG1 IL-36R Phase 2/3 Ulcerative colitis Eli"/>
  <result pre="virus surface antigen Phase 2/3 Hepatitis B virus-associated liver transplant" exact="Biogen" post="Aducanumab Human IgG1 Amyloid beta Phase 3 Alzheimer’s disease"/>
  <result pre="Biogen Aducanumab Human IgG1 Amyloid beta Phase 3 Alzheimer’s disease" exact="Genentech" post="Crenezumab Humanized IgG4 Amyloid beta Phase 3 Alzheimer’s disease"/>
  <result pre="Crenezumab Humanized IgG4 Amyloid beta Phase 3 Alzheimer’s disease Hoffmann-La" exact="Roche" post="Gantenerumab Human IgG1 Amyloid beta Phase 3 Alzheimer’s disease"/>
  <result pre="Gantenerumab Human IgG1 Amyloid beta Phase 3 Alzheimer’s disease Hoffmann-La" exact="Roche" post="Faricimab Bispecific CrossMab VEGF-A, Ang2 Phase 3 Diabetic macular"/>
  <result pre="Faricimab Bispecific CrossMab VEGF-A, Ang2 Phase 3 Diabetic macular edema" exact="Novartis" post="Brolucizumab Humanized scFv VEGF-A Phase 3 Neovascular age-related macular"/>
  <result pre="evaluation as a treatment for neovascular age-related macular degeneration (nAMD)." exact="Novartis" post="has indicated that regulatory submissions for brolucizumab may occur"/>
  <result pre="brolucizumab may occur in December 2018. 62 In October 2018," exact="Novartis" post="released 96-week results from the Phase 3 HAWK (NCT02307682)"/>
  <result pre="and EU for the treatment of sickle cell-related pain crises." exact="Novartis" post="anticipates submitting a BLA in 2019. 71 Satralizumab (SA237;"/>
  <result pre="Study (NCT02028884) of were presented at the 2018 Congress of" exact="European Committee for Treatment and Research in Multiple Sclerosis" post="held October 10–12, 2018, in Berlin, Germany. In this"/>
  <result pre="orphan designations for the treatment of NMOSD. According to the" exact="Roche" post="pipeline listing, an application submission for satralizumab is anticipated"/>
  <result pre="cancer pain, and chronic low back pain. In July 2018," exact="Pfizer" post="and Lilly announced positive results from a 16-week Phase"/>
  <result pre="ADC CD19 Pivotal Phase 2 Diffuse large B-cell lymphoma Hoffmann-La" exact="Roche" post="Polatuzumab vedotin Humanized IgG1 ADC CD79b Phase 3 Diffuse"/>
  <result pre="Humanized IgG1 ADC CD79b Phase 3 Diffuse large B-cell lymphoma" exact="Pfizer" post="Utomilumab Human IgG2 4-1BB (CD137) Phase 3 Diffuse large"/>
  <result pre="MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse large B-cell lymphoma" exact="Sanofi" post="Isatuximab Humanized IgG1 CD38 Phase 3 Multiple myeloma Jiangsu"/>
  <result pre="Chimeric IgG1 Claudin-18.2 Phase 3 Gastric and gastro-esophageal junction adenocarcinoma" exact="Gilead Sciences" post="Andecaliximab Humanized IgG4 MMP9 Phase 3 Gastric cancer or"/>
  <result pre="IgG4 MMP9 Phase 3 Gastric cancer or gastroesophageal junction adenocarcinoma" exact="AbbVie" post="Depatuxizumab mafodotin IgG1 ADC EGFR Phase 2b/3 Glioblastoma Y-mabs"/>
  <result pre="GD2 Phase 3 High risk neuroblastoma and refractory osteomedullary disease" exact="Bristol-Myers Squibb" post="Relatlimab (BMS-986016) Human mAb LAG-3 Phase 2/3 Melanoma Biocad"/>
  <result pre="2/3 Melanoma Biocad BCD-100 Human mAb PD-1 Phase 2/3 Melanoma" exact="Novartis" post="Spartalizumab, PDR001 Humanized IgG4 PD-1 Phase 3 Melanoma Philogen"/>
  <result pre="soravtansine IgG1 ADC Folate receptor 1 Phase 3 Ovarian cancer" exact="AbbVie" post="Rovalpituzumab tesirine Humanized IgG1 ADC DLL3 Phase 3 Small"/>
  <result pre="Polatuzumab vedotin (DCDS4501A, RG7596; Roche) In collaboration with Seattle Genetics," exact="Roche" post="is developing polatuzumab vedotin, which is composed of a"/>
  <result pre="EU Orphan Drug designations for diffuse large B-cell lymphoma (DLBCL)." exact="Roche" post="has indicated that, based on positive clinical data from"/>
  <result pre="Phase 3 studies (ICARIA, IKEMA, and IMROZ) of MM patients." exact="Sanofi" post="expects results from ICARIA by Q1 2019; positive clinical"/>
  <result pre="estimated primary completion date of the study is July 2019." exact="Novartis" post="plans to submit marketing applications for PDR001 in combination"/>
  <result pre="dates in September 2019, November 2019, and September 2020. However," exact="AbbVie" post="announced in March 2018 that they will not seek"/>
  <result pre="CTCL cutaneous T-cell lymphoma DLBCL diffuse large B-cell lymphoma EC" exact="European Commission" post="EMA European Medicines Agency EpCAM epithelial cell adhesion molecule"/>
  <result pre="EpCAM epithelial cell adhesion molecule EU European Union FDA US" exact="Food and Drug Administration" post="FL follicular lymphoma HAE hereditary angioedema HCL hairy cell"/>
  <result pre="to the Therapeutic Antibody Database. References References 1. collab: The" exact="Royal Swedish Academy of Sciences" post="Scientific background on the Nobel Prize in Chemistry 2018:"/>
  <result pre="1): 73– 85. doi: 10.4161/mabs.27240 . 24262785 6. collab: The" exact="Royal Swedish Academy of Sciences" post="The Nobel Prize in Physiology or Medicine 2018. NobelPrize.org."/>
  <result pre="MAbs. 2010; 2( 1): 84– 100. 20065640 21. collab: US" exact="Food and Drug Administration" post="FDA approves novel preventive treatment for migraine. 5 17,"/>
  <result pre="for migraine. 5 17, 2018 press release https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608120.htm?utm_campaign=05172018_PR_FDA%20approves%20migraine%20prevention%20treatment&amp;amp;utm_medium=email&amp;amp;utm_source=Eloqua. 22. collab:" exact="Teva Pharmaceutical Industries" post="Ltd Teva announces U.S. approval of AJOVY™ (fremanezumab-vfrm) injection,"/>
  <result pre="adults . 9 27, 2018 press release https://investor.lilly.com/news-releases/news-release-details/lillys-emgalitytm-galcanezumab-gnlm-receives-us-fda-approval. 25. collab:" exact="Kyowa Hakko Kirin" post="Co. Ltd, Kyowa Kirin International PLC, Ultragenyx Pharmaceutical Inc"/>
  <result pre="8): 1383– 1393. doi: 10.1002/jbmr.3475 . 29947083 27. collab: US" exact="Food and Drug Administration" post="FDA approves first therapy for rare inherited form of"/>
  <result pre="angioedema . 8 23, 2018 press release https://www.shire.com/en/newsroom/2018/august/4fhgmy 29. collab:" exact="Sanofi" post="Cablivi™ (caplacizumab) approved in Europe for adults with acquired"/>
  <result pre="acquired thrombotic thrombocytopenic purpura . 59th Annual Meeting of the" exact="American Society of Hematology;" post="2017 12 12, Atlanta, GA https://www.ablynx.com/uploads/events/ca854140-58c3-4357-9695-4b81c1996c75-12dec2017_caplacizumabherculesash_final.pdf 31. collab: US"/>
  <result pre="Hematology; 2017 12 12, Atlanta, GA https://www.ablynx.com/uploads/events/ca854140-58c3-4357-9695-4b81c1996c75-12dec2017_caplacizumabherculesash_final.pdf 31. collab: US" exact="Food and Drug Administration" post="FDA approves treatment for two rare types of non-Hodgkin"/>
  <result pre=". 9 28, 2018 press release https://investor.regeneron.com/news-releases/news-release-details/fda-approves-libtayor-cemiplimab-rwlc-first-and-only-treatment 36. collab: US" exact="Food and Drug Administration" post="FDA approves new HIV treatment for patients who have"/>
  <result pre="7): 645– 654. doi: 10.1056/NEJMoa1711460 . 30110589 38. collab: US" exact="Food and Drug Administration" post="TROGARZO™ (ibalizumab-uiyk) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf 39. Reich K ,"/>
  <result pre="3): 615– 622. doi: 10.1111/bjd.16724 . 29742274 41. collab: US" exact="Food and Drug Administration" post="FDA approves first treatment specifically for patients with rare"/>
  <result pre="42. collab: Immunomedics Corporate overview. 9 2018 https://www.immunomedics.com/wp-content/uploads/2018/09/Corporate-Presentation-September-2018.pdf 43. collab:" exact="Alexion Pharmaceuticals" post="FDA accepts priority review of ALXN1210 as a treatment"/>
  <result pre="US . 8 20, 2018 press release http://ir.alexion.com/news-releases/news-release-details/fda-accepts-priority-review-alxn1210-treatment-patients 44. collab:" exact="Alexion Pharmaceuticals" post="Alexion announces positive top-line results showing successful phase 3"/>
  <result pre="(PNH) . 3 15, 2018 press release https://news.alexion.com/press-release/product-news/alexion-announces-positive-top-line-results-showing-successful-phase-3-cl. 45. collab:" exact="AbbVie" post="AbbVie submits biologics license application to U.S. FDA for"/>
  <result pre=". 3 15, 2018 press release https://news.alexion.com/press-release/product-news/alexion-announces-positive-top-line-results-showing-successful-phase-3-cl. 45. collab: AbbVie" exact="AbbVie" post="submits biologics license application to U.S. FDA for investigational"/>
  <result pre="392( 10148): 650– 661. doi: 10.1016/S0140-6736(18)31713-6 . 30097359 47. collab:" exact="Amgen" post="and UCB Amgen and UCB provide update on regulatory"/>
  <result pre="661. doi: 10.1016/S0140-6736(18)31713-6 . 30097359 47. collab: Amgen and UCB" exact="Amgen" post="and UCB provide update on regulatory status of EVENITY™"/>
  <result pre="in the US . 7 16, 2017 https://www.amgen.com/media/news-releases/2017/07/amgen-and-ucb-provide-update-on-regulatory-status-of-evenity-romosozumab-in-the-us/. 48. collab:" exact="Amgen" post="and UCB Amgen and UCB resubmit biologics license application"/>
  <result pre=". 7 16, 2017 https://www.amgen.com/media/news-releases/2017/07/amgen-and-ucb-provide-update-on-regulatory-status-of-evenity-romosozumab-in-the-us/. 48. collab: Amgen and UCB" exact="Amgen" post="and UCB resubmit biologics license application (BLA) for EVENITY™"/>
  <result pre="treatment in patients with relapsed/refractory classical Hodgkin lymphoma . 2018" exact="American Society of Clinical Oncology" post="meeting abstract https://meetinglibrary.asco.org/record/162336/abstract. 55. Zhou C , Gao G"/>
  <result pre="advanced non-squamous non-small cell lung cancer (NSCLC) patients . 2018" exact="American Society of Clinical Oncology" post="meeting abstract https://meetinglibrary.asco.org/record/160803/abstract. 56. Xu JM , Zhang Y"/>
  <result pre="dose . 11 13, 2018 press release https://www.cytodyn.com/media/press-releases/detail/297/cytodyns-pro-140-leronlimab-hiv-monotherapy-trial. 62. collab:" exact="Novartis" post="New analysis of Novartis phase III brolucizumab (RTH258) data"/>
  <result pre="2018 press release https://www.cytodyn.com/media/press-releases/detail/297/cytodyns-pro-140-leronlimab-hiv-monotherapy-trial. 62. collab: Novartis New analysis of" exact="Novartis" post="phase III brolucizumab (RTH258) data reinforces superior reduction of"/>
  <result pre="nAMD . 9 22, 2018 press release https://www.novartis.com/news/media-releases/new-analysis-novartis-phase-iii-brolucizumab-rth258-data-reinforces-superior-reduction-retinal-fluid-key-marker-disease-activity-namd. 63. collab:" exact="Novartis" post="Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept"/>
  <result pre="2018 press release https://www.novartis.com/news/media-releases/new-analysis-novartis-phase-iii-brolucizumab-rth258-data-reinforces-superior-reduction-retinal-fluid-key-marker-disease-activity-namd. 63. collab: Novartis Two-year data for" exact="Novartis" post="brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid"/>
  <result pre="J Hematol. 2018 10 8. doi: 10.1002/ajh.25308 . 71. collab:" exact="Novartis" post="Novartis analysis shows crizanlizumab (SEG101) increased the number of"/>
  <result pre="Hematol. 2018 10 8. doi: 10.1002/ajh.25308 . 71. collab: Novartis" exact="Novartis" post="analysis shows crizanlizumab (SEG101) increased the number of patients"/>
  <result pre="2017; 40:. 307– 325. doi: 10.1146/annurev-neuro-072116-031121 . 28441116 74. collab:" exact="Pfizer" post="Inc., Eli Lilly and Company Pfizer and Lilly announce"/>
  <result pre="307– 325. doi: 10.1146/annurev-neuro-072116-031121 . 28441116 74. collab: Pfizer Inc.," exact="Eli Lilly and Company" post="Pfizer and Lilly announce positive top-line results from phase"/>
  <result pre=". 28441116 74. collab: Pfizer Inc., Eli Lilly and Company" exact="Pfizer" post="and Lilly announce positive top-line results from phase 3"/>
  <result pre="pain . 7 18, 2018 press release https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_lilly_announce_positive_top_line_results_from_phase_3_trial_of_tanezumab_for_the_treatment_of_osteoarthritis_oa_pain. 75. collab:" exact="Eli Lilly and Company" post="Form 10-Q quarterly report for the quarter ended 6"/>
  <result pre="a phase 2 clinical trial . 23rd Congress of the" exact="European Hematology Association," post="2018 6 16; Stockholm, Sweden https://www.primeoncology.org/app/uploads/hematology-updates-stockholm-2018-dlbcl-s802-sehn.pdf 77. collab: Roche"/>
  <result pre="Hematology Association, 2018 6 16; Stockholm, Sweden https://www.primeoncology.org/app/uploads/hematology-updates-stockholm-2018-dlbcl-s802-sehn.pdf 77. collab:" exact="Roche" post="Roche virtual late stage pipeline event 2018. 9 13,"/>
  <result pre="Association, 2018 6 16; Stockholm, Sweden https://www.primeoncology.org/app/uploads/hematology-updates-stockholm-2018-dlbcl-s802-sehn.pdf 77. collab: Roche" exact="Roche" post="virtual late stage pipeline event 2018. 9 13, 2018"/>
  <result pre="event 2018. 9 13, 2018 corporate presentation https://www.roche.com/dam/jcr:8142e2f9-9525-4a8f-ad1f-d5f605e36991/en/irp20180913.pdf 78. collab:" exact="Sanofi" post="Q3 2018 results. 10 31, 2018 corporate presentation, slides"/>
  <result pre="5; 14( 11): 1035– 1047. doi: 10.2217/fon-2017-0616 . 29268619 80." exact="Novartis" post="AG Q2 2018 Results. 7 18, 2018 investor presentation,"/>
  <result pre="2018 investor presentation, slides 36, 37, 81. https://www.novartis.com/sites/www.novartis.com/files/q2-2018-ir-presentation.pdf. 81. collab:" exact="Novartis" post="Q2 results confirm full year guidance. Strong pipeline results"/>
  <result pre="3 trial. 9 25, 2018 press release http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-update-regarding-unity-cll-phase-3. 93. collab:" exact="AbbVie" post="AbbVie announces results from phase 2 study evaluating rovalpituzumab"/>
  <result pre="trial. 9 25, 2018 press release http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-update-regarding-unity-cll-phase-3. 93. collab: AbbVie" exact="AbbVie" post="announces results from phase 2 study evaluating rovalpituzumab tesirine"/>
 </snippets>
</snippetsTree>
